This study compared the efficacy of therapy with the double beta-lactam combination of ceftazidime plus piperacillin with that of single-agent therapy with 
combination had no advantage over single-agent therapy and was in all cases clearly inferior to beta-lactamaminoglycoside combinations.
Synergistic antimicrobial combinations for empiric therapy of febrile, granulocytopenic patients frequently include an aminoglycoside for enhanced activity against gramnegative aerobic bacilli (6) . Although effective in treating infections caused by those organisms, aminoglycosides are associated with the development of ototoxicity and nephrotoxicity (11, 13) . To avoid these side effects, double beta-lactam combinations have been investigated as alternatives to aminoglycoside-containing combinations and have been used in prospective clinical trials for empiric therapy of suspected sepsis in febrile granulocytopenic patients (12; C. de (8) . Since P. aeruginosa is an important pathogen in granulocytopenic patients (2) , the enhanced in vitro activity Qf ceftazidime against this organism suggests that it may be a better candidate for inclusion in a double beta-lactam combination than moxalactam or ticarcillin.
Normal and granulocytopenic rats infected with gramnegative organisms have been used in several assessnlents of * Corresponding author. the activities of antimicrobial drugs and their combinations (1, 4, 7, 10 Walkersville, Md.) were conditioned in our laboratory for 1 week after receipt from the breeder. During the conditioning period, stool cultures were examined to ensure that animals were not colonized with P. aeruginosa. During conditioning and throughout the experiment, rats had free access to rat chow and fresh drinking water which was acidified to prevent contamination with P. aeruginosa. Noninfected neutropenic control rats remained free of P. aeruginosa throughout the experiment.
Induction of neutropenia. Cyclophosphamide (Mead Johnson, Evansville, Ind.) was administered i.p. in doses of 100 mg/kg of body weight on day 0 and 75 mg/kg of body weight on day 4. Leukocyte (WBC) counts were taken daily on noninfected rats to assess the effect of cyclophosphamide. Differential counts were taken on Wrightstained smears. As demonstrated previously (4), cyclophosphamide therapy effected a reduction in the mean WBC count from 12,700 WBCs per p.1 on day 0 to 470 WBCs per ,u1 on day 5 and maintenance of the count at the latter level throughout the therapeutic period (days 5 to 8). Reduction in total WBC count was accompanied by a reduction in -granulocytes. On day 0, the mean granulocyte count was 1,905 granulocytes per ,ul, and on days 5 through 8 it was <50 granulocytes per Il. Antimicrobial agents. Piperacillin, ceftazidime, and amikacin were studied. All of the antibiotics used in rats were from vials prepared for clinical use. Reference solutions of each agent for pharmacokinetic studies were prepared from standardized antibiotic powders supplied by the manufacturers.
In vitro susceptibility studies. MIC, MBC, and tests of synergy for several P. aeruginosa clinical blood culture isolates were determnined by the microtiter variation of the checkerboard technique (5)-. For studies of beta-lactamaminoglycoside synergy, serial twofold dilutions of piperacillin or ceftazidime, prepared in Mueller-Hinton broth (BBL) containing 50 ,ug of Ca2+ per ml and 25 ,ug of Mg2+ per ml (0.05 ml per well), were made in one direction with an automatic diluter (Dynatech Laboratories, Inc., Alexandria, Va.). Twofold dilutions of amikacin were added manually in the perpendicular direction (0.05 ml per well). For double beta-lactam synergy studies, serial twofold dilutions of piperacillin were made in one direction, and serial twofold dilutions of ceftazidime were made in the perpendicular direction. For each strain of P. aeruginosa tested, a dilution of an overnight culture was added to each well (0.0015 ml per well) to yield a final concentration of approximately 5 X 105 CFU/ml. The contents of each microtiter tray were mixed, and the trays were covered and incubated at 37°C overnight.
The MIC was defined as the lowest antibiotic concentration that prevented visible growth. A 0.0015-ml sample from each MIC microtiter well was inoculated onto a Trypticase soy agar plate which was incubated at 37°C overnight. The MBC was defined as the lowest antibiotic concentration producing .99.9% reduction in viable bacteria, the endpoint being no growth. Synergy was defined as a fourfold or greater reduction in the MBC of both antibiotics in the combination when compared with the MBC of the individual antibiotics.
Concentrations of antimicrobials in rat serum. Antimicrobial rat serum concentration studies were performed in normal, noninfected rats so that equivalent antibiotic doses could be identified for use in therapeutic trials. Criteria for equivalent doses included: (i) rat serum levels at 30 min after administration similar to attainable serum levels in humans, and (ii) rat serum antibiotic levels approximately equal to the MBC of the challenge organism 2 h after administration of antibiotic. Piperacillin and amikacin were given intramuscularly, and ceftazidime was given subcutaneously. Rats were injected with various doses of these three antibiotics (three rats per dose) and then were bled retro-orbitally at 0. (Fig. 1) . These doses were used in the therapeutic trials.
Therapeutic trials. Antibiotic efficacy against each of two different-sized bacterial challenges was evaluated. At the 5-LD50 challenge level, all of the therapeutic regimens provided some protection. The survival rate With amikacin alone was clearly greater than that with either piperacillin or ceftazidime (P 0.005) and was similar to that attained with piperacillin plus ceftazidime (P 0.18). Differences between survival rates after therapy with amikacin plus either piperacillin or ceftazidime and therapy with piperacillin plus ceftazidime approached significance (P -0.056).
At the 50-LD50 challenge level, survival in. the groups treated with piperacillin, ceftazidime, or amikacin alone, and in the groups treated with piperacillin combined with cefta- VOL. 27, 1985 on July 9, 2017 by guest http://aac.asm.org/ Downloaded from zidime and saline, was similar (P 2 0.11) and clearly inferior to survival accorded by combination therapy of amikacin plus piperacillin or ceftazidime (P . 0.001). Proportional-hazard model analysis (3) of survival curves of rats challenged with 5 and 50 LD50s of P. aeruginosa 25 (Table 1 ) was used to describe interactions between antimicrobial agents used in combination therapy. At both challenge levels, results of the analysis for the aminoglycosidecontaining combinations were consistent with the hypothesis that the antimicrobial agents interacted in a multiplicative fashion which may be analogous to synergistic interaction in vitro. At the 50-LD50 challenge level, results of analysis of the piperacillin-ceftazidime combination suggested a lessthan-multiplicative interaction (P = 0.07) that is not significant at the a = 0.05 level.
Rate of bacteremia and emergence of resistant organisms. Within each therapeutic group, the number of bacteremic animals was similar to the number of animals that died (Table 1) . Dead animals were usually bacteremic, but the challenge organism was recovered infrequently from blood cultures of rats that were alive 72 h after challenge.
P. aeruginosa isolates from rat blood cultures were tested for susceptibility to the antibiotics used in therapy. The MICs and MBCs of resistant organisms (defined as fourfold or greater change over the challenge organism) were usually four or eightfold greater than those of the challenge organism. Highly resistant organisms were not recovered. Differences in the rates of recovery of resistant P. aeruginosa between challenge groups (i.e., 5 and 50 LD50s), regardless of the therapeutic regimen, were not significant (P -0.13). For animals receiving single-agent therapy, differences in the emergence of resistant organisms were also not significant (P 2 0.13). Differences in the rates of emergence of resistant organisms between single-agent therapy and therapy with the double beta-lactam combination were not significant (P -0.17). In contrast, differences in the rates of emergence of resistant organisms were greater with single-agent therapy than with the aminoglycoside-beta-lactam combinations (P c0.05).
DISCUSSION
The overall efficacies of double beta-lactam combinations and aminoglycoside-containing combinations in the treatment of febrile episodes among granulocytopenic cancer patients have been similar in randomized prospective trials. However, therapeutic efficacy of double beta-lactam combinations against P. aeruginosa infections frequently could not be analyzed because of the small number of patients with such infections. As (Fig. 1) . Lastly, the numbers of bacteremic rats and the emergence of resistant organisms following therapy were similar for animals treated with single agents or with the double-beta-lactam combination. Each of these regimens was inferior to the aminoglycoside-beta-lactam combinations.
